Later, Rotin et al. [28] observed that ibrutinib synergised daunorubicin on BTK-knockdown AML cells without increasing its accumulation, thus discarding BTK or MRP1 inhibition as the mechanism underlying this synergism. The gene discussed is ABCC1; the disease is acute myeloid leukemia.